Kumar R, Mandal M, Lipton A, Harvey H, Thompson C B
Departments of Medicine and Cellular, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Clin Cancer Res. 1996 Jul;2(7):1215-9.
Overexpression of HER2 in estrogen receptor (ER)-positive human breast tumors has been associated with resistance to endocrine therapy. Here we investigated the effects of HER2 on expression of apoptotic pathways and modulation of tamoxifen-induced apoptosis in ER-positive MCF-7 breast cancer cells. We report that HER2 overexpression in MCF-7 cells is accompanied by up-regulation of antiapoptotic Bcl-2 and Bcl-XL proteins and suppression of tamoxifen-induced apoptosis. In addition, human tumor cell lines that are both ER positive and overexpress HER2 also express enhanced levels of Bcl-2 compared to cells that are either ER positive or overexpress HER2 alone. Our findings suggest that possible deregulation of antiapoptotic Bcl-2 and Bcl-XL may be associated with the enhanced survival of HER2-overexpressing and ER-positive breast cancer cells treated with antiestrogens.
人雌激素受体(ER)阳性乳腺肿瘤中HER2的过表达与内分泌治疗耐药相关。在此,我们研究了HER2对ER阳性MCF-7乳腺癌细胞凋亡途径表达的影响以及他莫昔芬诱导的细胞凋亡的调节作用。我们报告称,MCF-7细胞中HER2的过表达伴随着抗凋亡蛋白Bcl-2和Bcl-XL的上调以及他莫昔芬诱导的细胞凋亡的抑制。此外,与单独ER阳性或单独HER2过表达的细胞相比,ER阳性且HER2过表达的人肿瘤细胞系也表达更高水平的Bcl-2。我们的研究结果表明,抗凋亡蛋白Bcl-2和Bcl-XL可能的失调可能与HER2过表达且ER阳性的乳腺癌细胞在用抗雌激素治疗后的生存增强有关。